The recombinant urate oxidase, rasburicase (Elitekt, SanofiSynthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drugrelated adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.
Introduction
Patients with hematologic malignancies or bulky solid tumors are at increased risk of developing hyperuricemia and tumor lysis syndrome (TLS) while undergoing intensive chemotherapy. [1] [2] [3] These complications add to patient's morbidity and mortality, and may affect the ability to deliver chemotherapy in a timely fashion. Historically, as high as 25% of children with advanced-stage Burkitt's lymphoma or mature B-cell leukemia would develop acute renal failure after the initiation of intensive chemotherapy despite prophylaxis. 4, 5 Until recently, allopurinol, hydration, alkalinization and diuresis have been the standard measures to prevent or treat hyperuricemia in patients with cancer. 6, 7 Allopurinol inhibits the enzyme xanthine oxidase, preventing further uric acid production, while alkalinization and hydration increase solubility and hence renal clearance of uric acid. However, despite allopurinol treatment, patients still have to excrete existing pools of uric acid and it may take several days for levels to decline. An additional, potential disadvantage is the accumulation of xanthine, a less soluble compound than uric acid, which results from xanthine oxidase inhibition, and could lead to xanthine nephropathy and urolithiasis. [8] [9] [10] Unlike allopurinol, the enzyme urate oxidase is a uricolytic agent. It catalyses the conversion of uric acid to allantoin, which is 5-10 times more soluble than uric acid, and is therefore readily excreted by the kidneys. 11 It is present in many mammalian species, but not in humans. Nonrecombinant urate oxidase extracted from Aspergillus flavus has been shown to be more effective than allopurinol in the prevention and treatment of hyperuricemia, but was associated with acute hypersensitivity reactions that manifested as bronchospasm and hypoxemia in approximately 5% of patients. 12 A recombinant urate oxidase (rasburicase, Elitekt) has recently been developed and evaluated in a series of clinical trials. [13] [14] [15] [16] In a randomized trial, rasburicase was more effective than allopurinol in controlling hyperuricemia, and had an earlier onset of action.
14 It was approved in 2002 by the Food and Drug Administration of the United States for use in pediatric patients.
To provide patients at high risk of tumor lysis syndrome with this drug before it became commercially available, two parallel and identical compassionate-use trials were initiated in 1999, one enrolled patients in Europe and Australia 15 and the other in North America. Initial results of the first 245 patients in the North American study have been reported. 16 Here, we present the final results for the 1069 patients (682 children and 387 adults) treated in the North American study.
Patients and methods

Eligibility criteria
Patients with cancer presenting with or at risk of acute hyperuricemia and TLS were eligible in this multicenter, openlabel study. There were no age limits and informed consent was obtained from all patients or their guardians. Patients were excluded if they were pregnant or lactating, had a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, atopic allergy, asthma or hypersensitivity reaction to rasburicase or non-recombinant urate oxidase. Patients who had received prior therapy with rasburicase or non-recombinant urate oxidase were eligible, provided at least 7 days had elapsed between treatments.
Treatment plan
Rasburicase (Elitekt, Sanofi-Synthelabo, Inc.) at a dose of 0.20 mg/kg was diluted to a final volume of 50 ml with preservative-free sodium chloride and administered intravenously as a 30-min infusion daily for 1-7 days (dosing volume ranged from 10-50 ml in infant patients). Patients could be treated every 12 h with rasburicase for the first 72 h according to the physician's judgment. Other hypouricemic agents, for example, allopurinol, were discontinued prior to initiation of rasburicase therapy. No wash-out period before rasburicase initiation was required, as in many patients the decision to change from allopurinol to rasburicase was made because of elevation of uric acid levels despite allopurinol therapy. While participating centers were advised that alkalinization is not required when using rasburicase, and that overzealous alkalinization could enhance calcium-phosphate precipitation, 17 management of intravenous fluids was left to the treating physician.
Patient evaluation
Baseline laboratory evaluations included a leukocyte count, serum lactate dehydrogenase, and serum or plasma uric acid levels. Serum or plasma uric acid levels were measured at the discretion of the investigators, but were required 24-48 h after the last dose of rasburicase. Patients were monitored for adverse events during drug administration, as well as at 24-48 h and at 1 week after completion of rasburicase administration. Patients were followed for serious adverse events for 30 days after the last dose of rasburicase administration.
Statistical considerations and response criteria
Patients who received at least one dose of rasburicase and had uric acid levels measured both pre-and post-treatment were included in the analysis of efficacy. Efficacy of the subsequent courses given to 71 patients was analyzed separately. All patients who had received one or more doses of rasburicase were included in the safety analysis. Patients were categorized as being hyperuricemic (baseline uric acid levels above the upper limit of normal for age and sex) or nonhyperuricemic (baseline uric acid level at or below the upper limit of normal for age and sex) at baseline. 18 Pre-treatment and post-treatment uric acid levels were compared using a paired t-test. Response was defined as achievement of normal uric acid levels for the hyperuricemic cohort and maintenance of normal uric acid levels for the nonhyperuricemic cohort at the post-treatment evaluation (24-48 h after the last dose). However, uric acid levels obtained after the first dose of rasburicase and prior to 5 days after the last dose of rasburicase were included in the assessment of efficacy. For patients with more than one uric acid level measured within this period, the value that was obtained closest to and after 24 h was used, if available. Otherwise, the value closest to 24 h was used. Adverse events were coded using World Health Organization criteria.
Results
Between January 1999 and September 2002, 1069 patients (682 children and 387 adults) with hematologic malignancies or solid tumors were enrolled on this compassionate-use trial at 41 centers (39 in the US and two in Canada). Baseline patient characteristics are summarized in Table 1 . The median ages of the pediatric and adult populations were 7 and 54 years, respectively. The most frequent diagnoses were acute lymphoblastic leukemia (ALL) in the pediatric cohort, and nonHodgkin's lymphoma (NHL) and acute myeloid leukemia (AML) in the adult cohort. Most patients had a high tumor burden, as evidenced by a markedly elevated median lactic dehydrogenase (LDH) level and by a high median leukocyte count. Over one-third of the pediatric patients had advanced Bor T-cell NHL or T-cell ALL; 90 children (13.1%) had B-cell disease and 148 (22%) had T-cell disease. In the adult group, these numbers were 38 (9.8%) and 23 (5.9%), respectively.
Efficacy
Of the 1069 treated patients, 996 (658 children and 338 adults) were evaluable for efficacy ( Table 2 ). All patients who received rasburicase prophylactically (260 children and 126 adults) maintained low uric acid levels despite ongoing chemotherapy. There was also a significant (Po0.001) decline in uric acid levels in 398 children and 212 adults, who had elevated uric acid levels at study entry. All hyperuricemic adults and 98.5% of the hyperuricemic children responded to rasburicase treatment.
Only six children with elevated uric acid levels at baseline failed to respond by study criteria. Details are provided below.
Patient 1, a 10-year-old male with T-cell ALL and a baseline white blood cell count (WBC) of 187.9 Â 10 9 /l, received only one dose of rasburicase. Although the uric acid level decreased from 11.2 to 7.7 mg/dl, he died of hyperkalemia-induced arrhythmia on day 2 of the study.
Patient 2, a 16-year-old female with pre B-cell ALL and a WBC of 96.3 Â 10 9 /l, received three doses of rasburicase. Her uric acid level decreased from 9.8 to 7.7 mg/dl, and she was taken off study as the investigator considered her treatment completed.
Patient 3, an 8-month-old female with pre-B-cell ALL and a WBC of 44.5 Â 10 9 /l, received two doses of rasburicase. Her uric acid decreased from 10.8 to 7.2 mg/dl, and she was taken off study as the investigator considered that treatment was completed. Rasburicase is effective and safe in treating hyperuricemia S Jeha et al Patient 4, a 9-year-old male with NHL, experienced a decrease in uric acid from 11.0 to 8.1 mg/dl after one dose of rasburicase. He was withdrawn from the study immediately thereafter because he was found to be ineligible due to a history of asthma.
Patient 5, a 15-year-old male with mature B-cell ALL, received two doses of rasburicase. The uric acid level decreased from 20.5 to 8.8 mg/dl. On day 2, he developed a mild (grade 1) maculopapular rash that responded to diphenhydramine. Although the relationship to the study drug was recorded as 'unknown', the patient was withdrawn from the study.
Patient 6, a 7-year-old female with early B-cell ALL, presented with a 125 Â 10 9 /l leukocyte count, and a uric acid level of 11.2 mg/dl. The day after the first dose of rasburicase, the uric acid had declined to 0.2 mg/dl. She received no further doses until 6 days later when the uric acid had risen again to 11.2 mg/dl. No uric acid levels after the second dose were available.
In summary, five of the six 'nonresponders' discontinued treatment after one or two doses of rasburicase, and only one nonresponder received three doses. Notably, uric acid levels decreased after treatment in all nonresponders.
Treatment duration and reasons for treatment discontinuation
The median number of doses was three (range, 1-14) and days of treatment three (range, 1-12). Chemotherapy initiation was delayed in one patient, and the treating physician was granted permission to continue rasburicase until completion of chemotherapy. All other patients were treated according to guidelines. The majority of patients were treated for only 1-4 days; 40.0% of children and 20.4% of adults received treatment for 5 or more days.
In all, 17 patients (1.6%) were withdrawn from the study for an adverse event. In 10 of these patients, the event was considered to be related to rasburicase or of unknown etiology as described in the Safety section. In all, 46 patients (4.3%) died before the completion of the study. None of the deaths were considered to be related to rasburicase. They were attributed to the underlying malignancy or to the complications of chemotherapy. A total of 11 patients stopped treatment for reasons categorized as 'other'; none were related to adverse events.
Repeated administration
In total, 71 patients (25 children, 46 adults) re-entered the study at least once and received additional courses (Table 3) . Altogether, 54 patients received a total of two courses; nine received three courses; eight received X4 courses, with one patient receiving a total of 16 courses. Only one patient who was re-entered and received one dose of rasburicase, as prophylaxis did not maintain a normal uric acid level.
Safety of single course
All 1069 patients were included in the safety analysis. Safety data are reported separately for the first course of treatment and for subsequent courses for retreated patients. In all, 69 events in 26 children (48 events) and 18 adults (21 events) were considered to be likely related to rasburicase, or of unknown etiology ( Table 4 ). The most frequent adverse reactions were headache (0.7%), rash (0.4%), fever (0.3%) and vomiting (0.3%). The majority of the events were mild (grade 1 or 2). In all, 13 patients (11 children, two adults) had a total of 25 grade 3 or 4 events, which were likely related to rasburicase treatment (n ¼ 10) or of unknown etiology (n ¼ 15). The grade 3 events included four cases of hemolytic anemia (G6PD deficiency was diagnosed in one patient subsequently), one TLS, one fever, one albuminuria, one allergic reaction and one dyspnea. Grade 4 events included two methemoglobinemia, two hypoxia, one anaphylactic shock, one rigor and one convulsion due to hypertensive encephalopathy. The remaining grade 3 and 4 events were electrolyte abnormalities.
A total of 13 patients (1.2%) experienced adverse events (any grade) that were likely hypersensitivity reactions. A total of 10 patients had events that led to withdrawal after the first course. These events included methemoglobinemia and skin rashes in two cases each; and hemolytic anemia with G6PD deficiency, anaphylaxis, allergic reaction, abdominal pain and throat numbness, respiratory distress with decreased oxygen saturation and urticaria, and fever with myalgia in one case each. A third patient reported an adverse event of methemoglobinemia that was not considered to be related to rasburicase by the investigator; however, the sponsor subsequently considered it to be possibly related. This patient did not discontinue rasburicase treatment. Rasburicase is effective and safe in treating hyperuricemia S Jeha et al
None of the on-study deaths were considered to be related to rasburicase treatment.
Safety of second and subsequent courses
Events that were related or of unknown etiology in the second course included grade 3 increase in liver transaminases, grade 1 urticaria and grade 3 rash with grade 1 pruritus in one child each. One adult experienced a reaction consisting of grade 1 flushing, grade 3 dyspnea, grade 3 involuntary muscle contractions and grade 3 chest pain during the second course. Rasburicase was discontinued and the patient recovered with treatment. Another adult had a reaction consisting of grade 2 chest pain and grade 3 dyspnea. Drug was discontinued and the patient recovered with treatment. A third adult had grade 3 back pain during the third course of treatment. During the fourth course of treatment, one child experienced grade 2 facial edema and one adult experienced an adverse event consisting of grade 1 flushing, hypotension, nausea, increased sweating, syncope and vomiting. Drug was discontinued and both patients recovered with treatment. These events occurred on the day of dosing and were consistent with allergic reactions.
Events consistent with allergic reactions were experienced by eight retreated patients (four adults and four children), and considered by the investigator to be related to the study drug in four (one child and three adults). These four events were grade 1 rash, grade 2 rash, grade 2 dyspnea and grade 3 dyspnea. No grade 4 events were reported. None of the three patients receiving more than four courses had an allergic reaction, including one patient who received 16 courses.
Most retreated patients had received two courses; 11% of the patients with reaction and 29% of those without reaction received more than two courses. The intervals between the courses among the patients with reaction were o1 month in 33.5%, 1-6 months in 44.5%, 6 months to 1 year in 11% and 41 year in 11%; they were 23, 55.5, 12.5 and 9%, respectively, among those without reaction.
Acute renal insufficiency
Acute renal insufficiency developed during the study in 45 patients (17 children and 28 adults). In all, 10 children and 20 adults underwent hemodialysis. The median age of patients undergoing dialysis was 50.5 years (range, . Their median baseline uric acid level was 10.4 mg/dl (range, 1.6-33.6 mg/dl); all patients but one child had resolution of hyperuricemia after rasburicase treatment (median number of doses three, range [1] [2] [3] [4] [5] [6] [7] [8] . Diagnoses were as follows: AML in 12 patients, NHL in eight, ALL in five, chronic lymphocytic leukemia (CLL) in two and chronic myelogenous leukemia (CML), plasma cell leukemia and multiple myeloma in one patient each. Five of 128 (3.9%) patients with advanced B-cell NHL and B-cell ALL, and two of 171 (1.2%) patients with advanced T-cell NHL and T-cell ALL required hemodialysis. The reason for hemodialysis was acute renal failure/azotemia associated with sepsis or chemotherapyrelated complication in 26 patients, six of whom were also reported to have TLS. The reason was hyperphosphatemia in the other four patients, of whom one patient also had hypocalcemia and two had azotemia. Nine patients with renal insufficiency also developed TLS, but did not require dialysis. One child and four adults who underwent dialysis died and none of the deaths were related to rasburicase treatment.
Discussion
While allopurinol inhibits uric acid synthesis, it does not degrade existing uric acid, and its administration can be associated with increased xanthine accumulation, leading to nephropathy. Alkalinization carries the risk of increased calcium phosphate precipitation in the renal tubules, which further compromises renal function. Rasburicase degrades existing uric acid. It lowers uric acid levels more rapidly than allopurinol, 13 does not cause accumulation of xanthine and does not require alkalinization, facilitating the phosphorus excretion. More than 1000 patients were treated with rasburicase on this study. Responses were observed in 99% of children and 100% of adults. Of six children considered as nonresponders to treatment, five received only one or two doses.
Hemodialysis is rarely required in patients treated with urate oxidase, despite the large tumor burden [12] [13] [14] (Table 5 ). Likewise, dialysis was performed in only 30 patients (2.8%) in this study. This rate is much lower than in children with similar diseases who were treated without urate oxidase. Of the 30 patients in this study, only six cases of acute renal failure were attributed to tumor lysis syndrome and four to hyperphosphatemia. In the remaining cases, renal insufficiency was associated with sepsis and other complications that occurred during intensive induction chemotherapy for hematologic malignancies. The rate of dialysis was 1.5% in children and 5% in adults. This low incidence of dialysis in adult patients is particularly remarkable, considering the number of patients with advanced age in this cohort.
Rasburicase was very well tolerated in both children and adults with a low incidence of adverse events. The majority of the events observed in this trial were mild. Only 10 of 1069 patients (o1%) were withdrawn for events that were possibly drug-related. During the first treatment course, 12 patients (1.1%) experienced possible hypersensitivity reactions (pruritus, hives, rash, urticaria, wheezing or edema) and one patient had an anaphylactic reaction. The incidence of hypersensitivity reactions was much lower in this and other studies of patients treated with rasburicase 13, [14] [15] [16] than was reported for the nonrecombinant product. 12, 19 In patients receiving repeated courses of rasburicase, the incidence of hypersensitivity reactions was slightly higher; however, all reactions were also mild and resolved readily with discontinuation of rasburicase. It should be noted that one of the byproducts of uric acid breakdown is hydrogen peroxide. Therefore, rasburicase should not be given to patients with a deficiency in G6PD because of the risk of inducing hemolysis.
11
Conclusion
The results of this large compassionate use study in over 1000 patients confirms the safety of rasburicase and provides further evidence of its efficacy in the prevention and treatment of hyperuricemia in adults and children undergoing chemotherapy for cancer. 
